Add to Calendar 5/14/2019 8:00:00 AM 5/14/2019 10:00:00 AM Latest China Patent Reforms & IP Strategies


CHINA. It’s the world’s second-largest national pharmaceutical market and also the biggest emerging market for pharmaceuticals. The China Food and Drug Administration (CFDA) has been busy implementing regulatory reforms and focused on prioritizing drug innovation and world class clinical trial standards. Simultaneously, China has been focused on patent law reform, making it a much more patent-friendly jurisdiction, benefiting innovators worldwide. Based on these facts alone it should be a no-brainer for your company to enter this market. Right? The question you always hear however is whether the opportunity justifies the (perceived) risks of doing business in China, particularly around the preserving the value of and protecting your intellectual property in China.

Learn all about the notable changes to China's patent laws from a China-based IP expert followed by an engaging panel discussion on strategies for protecting and maximizing the value of your intellectual property assets in China.

Notable changes to China’s Patent Law we will cover include:

  • Longer patent terms for innovative drugs and design patents
  • Creation of a specialized IP court system to provide greater consistency, quality, and efficiency in IP cases
  • Litigation reform such as significantly higher damage amounts and streamlined processes for suing infringers
  • New ways of rewarding innovators for their contributions  

Other topics that will be address will include the following:

  • The latest trends and best practices for investigating IP violations, including counterfeits, trade secret theft, and patent violations
  • Monitoring and enforcement of IP rights in online markets in China
  • Best practices in trademark protection, including measures to deal with preemptive trademark registrations by pirates, Chinese-language branding, and policing the register
MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139
Vice President at Eagle IP Limited
Jennifer is Partner and Vice President at Eagle IP, a patent firm based in Greater China. At Eagle IP, Jennifer works with foreign clients on cross-border IP strategy and helps them navigate China’s complicated and ever-changing IP landscape. Jennifer spent over ten years at Vertex Pharmaceuticals building up and overseeing global patent portfolios for the company’s UK and Canada research and development sites. Prior to joining Eagle IP, Jennifer was Vice President of IP and legal affairs at Axcella, a venture-back biotech startup focused on addressing metabolic dysregulation by leveraging amino acid biology. Jennifer has extensive experience in small molecules, large molecules, biotechnology, and nanotechnology-based therapeutics in a broad range of disease areas. Her working languages are English and Mandarin Chinese.